Rearch homepage new banner Nov 2013

Research

Our expertise research and development spans the entire life-cycle of a medicine. We have capabilities in both small molecules and biologics. This allows us to search for solutions to unmet medical needs using both modalities, individually or in combination


AstraZeneca & Karolinska Institutet: A new industry - academia partnership model

An IMED Collaboration Update

AstraZeneca has collaborated with Karolinska Institutet in Sweden, one of the world’s leading medical research universities, for many years on different projects. In 2013, we created a joint centre for research on cardiovascular and metabolic diseases. This goes deeper than the usual industry/academia partnership, as scientists from both partners work side-by-side in a dedicated university unit to develop new therapies for people in need. The ICMC aims to identify and validate novel targets within cardio-metabolic diseases, focusing on three strategic research areas: heart failure, diabetes and chronic kidney disease across both small molecules and biologics.

Download collaboration update (PDF 421kb)

View more collaboration updates


Our leaders iconOur leaders

All Directors are collectively responsible for the success of AstraZeneca. Discover general information,  images and biographies of our Board of Directors.

Read more


Pipeline iconOur pipeline

AstraZeneca's pipeline is one of the most exciting in the industry. Download the latest version of our development pipeline.

Read more


Path to meds iconPath to new medicines

The discovery, development and commercialisation of a medicine is a complex process. Information on our path to new medicines and an interactive overview are available.

Read more


Neuro iconAZ Neuroscience

Visit our dedicated neuroscience site for more information on our research and partnering in the area.

 

Visit site


Open innovation iconOpen innovation

Visit our Open Innovation site to see how we collaborate to push the boundaries of science and deliver life-changing medicines

Visit site


LabTalk is AstraZeneca’s science-focused blog where you can hear from scientists, researchers and academics discussing novel ideas, research and innovation.

Helping_to_steer_THM 26 March 2015

Helping to steer the largest genomics investment in the world

Risk_and_reoccurrence_THM 15 March 2015

Risk and reoccurrence in Cardiovascular Disease

Antidotes_for_antiplatelets_THM 13 March 2015

Antidotes for antiplatelets – why, what and when?